Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-09-05
2006-09-05
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S235200, C544S143000, C544S154000, C544S166000
Reexamination Certificate
active
07101877
ABSTRACT:
Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia.
REFERENCES:
patent: 2954380 (1960-09-01), Shapiro et al.
patent: 3218328 (1965-11-01), Shapiro et al.
patent: 4145435 (1979-03-01), Szmuszkovicz
patent: 4179501 (1979-12-01), Szmuszkovicz
patent: 4598087 (1986-07-01), Horwell
patent: 4656182 (1987-04-01), Horwell
patent: 4663343 (1987-05-01), Horwell et al.
patent: 4855316 (1989-08-01), Horwell et al.
patent: 4880800 (1989-11-01), Wallis
patent: 4906655 (1990-03-01), Horwell et al.
patent: 5019588 (1991-05-01), Horwell et al.
patent: 5051428 (1991-09-01), Horwell et al.
patent: 5059620 (1991-10-01), Stout et al.
patent: 5492825 (1996-02-01), Jan et al.
patent: 5506257 (1996-04-01), MacLeod et al.
patent: 5637583 (1997-06-01), MacLeod et al.
patent: 5670335 (1997-09-01), Jan et al.
patent: 5728535 (1998-03-01), Lester et al.
patent: 5734021 (1998-03-01), Lester et al.
patent: 5750537 (1998-05-01), Nomura et al.
patent: 5817698 (1998-10-01), Brown et al.
patent: 5885984 (1999-03-01), MacLeod et al.
patent: 6174879 (2001-01-01), MacLeod et al.
patent: 6180632 (2001-01-01), Myers et al.
patent: 6210809 (2001-04-01), Okutomi et al.
patent: 6214809 (2001-04-01), Fermini et al.
patent: 6214810 (2001-04-01), Fermini et al.
patent: 6451819 (2002-09-01), Alanine et al.
patent: 6521619 (2003-02-01), Link et al.
patent: 6649603 (2003-11-01), Lum
patent: 2005/0026993 (2005-02-01), Beatch et al.
patent: 2005/0038256 (2005-02-01), Barrett et al.
patent: 2005/0070552 (2005-03-01), Fedida et al.
patent: 2005/0119315 (2005-06-01), Fedida et al.
patent: 2005/0209307 (2005-09-01), Bain et al.
patent: 1234808 (1988-04-01), None
patent: 1235122 (1988-04-01), None
patent: 2004575 (1990-06-01), None
patent: 2058502 (1993-06-01), None
patent: 2172513 (1995-03-01), None
patent: 2240728 (1997-09-01), None
patent: 2008391 (1997-12-01), None
patent: 2289055 (1999-01-01), None
patent: 2268590 (2000-10-01), None
patent: 2132841 (2001-03-01), None
patent: 2 259 260 (1974-06-01), None
patent: 2 658 401 (1978-07-01), None
patent: 3 517 901 (1985-12-01), None
patent: 0147085 (1985-07-01), None
patent: 0147085 (1985-07-01), None
patent: 0222533 (1987-05-01), None
patent: 0372466 (1990-06-01), None
patent: 0372466 (1990-06-01), None
patent: 0380063 (1990-08-01), None
patent: 0380063 (1990-08-01), None
patent: 0552386 (1993-07-01), None
patent: 0720605 (2001-12-01), None
patent: 215963 (1998-02-01), None
patent: 02-270864 (1990-11-01), None
patent: WO 93/19056 (1993-09-01), None
patent: WO 94/07843 (1994-04-01), None
patent: WO 94/14435 (1994-07-01), None
patent: WO 95/08544 (1995-03-01), None
patent: WO 95/28155 (1995-10-01), None
patent: WO 96/18615 (1996-06-01), None
patent: WO 96/23894 (1996-08-01), None
patent: WO 97/32857 (1997-09-01), None
patent: WO 97/49680 (1997-12-01), None
patent: WO 99/02159 (1999-01-01), None
patent: WO 99/03468 (1999-01-01), None
patent: WO 99/11252 (1999-03-01), None
patent: WO 99/16431 (1999-04-01), None
patent: WO 99/50205 (1999-10-01), None
patent: WO 99/50225 (1999-10-01), None
patent: WO 00/47547 (2000-08-01), None
patent: WO 00/51981 (2000-09-01), None
patent: WO 01/96335 (2001-12-01), None
patent: WO 03/105756 (2003-12-01), None
patent: WO 2004/008103 (2004-01-01), None
patent: WO 2004/098525 (2004-11-01), None
patent: WO 2004/099137 (2004-11-01), None
Adcock, J.J. et al., (2003) “RSD931, a novel anti-tussive agent acting on airway sensory nerves” Br J Pharm, 138:407-416.
Altria, Kevin D. et al., (2001) “Capillary Electrophoresis as a Routine Analytical Tool in Pharmaceutical Analysis” LCGC 19(9):972-985.
Amin, et al., (1996) “RPR 101821, a New Potent Cholesterol-lowering Agent: Inhibition of Squalene Synthase and 7-Dehydrocholesterol Reductase”, Naunyn-Schmiedeberg's Arch Pharmacol 353:233-240.
Bain, et al., (1997) “Better Antiarrhythmics? Development of Antiarrhythmic Drugs Selective for Ischaemia-Dependent Arrhythmias”, Drug Development Research 42:198-210.
Barrett, T.D. (2000) “Ischaemia selectivity confers efficacy for suppression of ischaemia-induced arrhythmias in rats” Eur J Pharm, 398:365-374.
Barrett, T. D. et al., (1997) “A model of myocardial ischemia for the simultaneous assessment of electrophysiological changes and arrhythmias in intact rabbits” J Pharmacol Toxicol Methods, 37:27-36.
Barrett, T.D. et al., (1996) “Atypical Dose Response curves for Antiarrhythmic Drugs” BPS Proceedings 115P.
Barrett, T. D. et al., (1996) “Glibenclamide Possesses Transient, Ischaemia Selective Class III Antiarrhythmic Actions But does not Prevent Ischaemic Arrhythmias” BPS Proceedings 116P.
Barrett, Terrance D. (1997) “Ischemia Selective Electrophysiological and antiarrhythmic actions of RSD1019 in ischemic cardiac tissue” J Mol Cell Cardiol, pp. 197.
Barrett, Terrance D. et al., (2000) “RSD 1019 suppresses ischaemia-induced monophasic action potential shortening and arrhythmias in anaesthetized rabbits” Br J Pharm, 131:405-414.
Beatch, et al., (2002) “Selectively Prolongs Atrial Refractoriness and Terminates AF in Dogs with Electricially Remodeled Atria”, (NASPE) North Amer. Soc. of Pacing & Electrophysiol. 24:698 (Abstract 702).
Beatch, G. et al., (2003) “Electrophysiological Profile of RSD1235, A New Drug for Conversion of Atrial Fibrillation” Abstracts from AHA Circulation ISSN 0009-7322.
Beatch, G. et al., “RSD1235 Rapidly and Effectively Terminates Atrial Fibrillation” Abstract submission ESC Congress Aug. 30-Sep. 3, 2003, in Vienna, Austria.
Beatch, G.N. et al., (1996) “Antihistamine-induced Ventricular Arrhythmias” BPS Proceedings 120P.
Beatch, G.N. et al., (1997) “Characterization of a Non-Human Primate Model of Drug-Induced Torsades De Pointes” Proc. West. Pharmacol. Soc., 40: 13-16.
Beatch, G. N. et al., “RSD1235, A Novel Atrial-Selective Antiarrhythmic Drug, Shows Rapid and Extensive Oral Absorption in Man” 12thInternational Congress on Cadiovascular Pharmacotherapy, May 7-10, 2003, Barcelona, Spain.
Beatch, G.N. et al., (2002) “RSD1235 Selectively Prolongs Atrial Refractoriness and Terminates AF in Dogs with Electrically Remodeled Atria” PACE 24(Part II):698. Abstract 702.
Beatch, G. N. et al., (2002) “Ventricular Fibrillation, and Uncontrolled Arrhythmia Seeking New Targets” Drug Develop Res 55:45-52.
Bian, et al., (1998) “Effects of K-opioid receptor stimulation in the heart and the involvement of protein kinase C” Brit. J. Pharmacol. 124:600-606.
Billman, (2003) “RSD-1235”, Current Opinion Investigational Drugs 4(3):352-354.
Boiadjiev, et al., (1996) “pH-Sensitive Exciton Chirality Chromophore..Solvatochromic Effects on Circular Dichroism Spectra”, Tetrahedron: Asymmetry 7(10):2825-2832.
Bowen, et al., (1992) “Characterization of the enantiomers of cis-n-[2-(3,4-Dichlorophenyl)Ethyl]-N-Methyl-2-(1-Pyrrolidinyl)Cyclohexylamine (BD737 and BD738): Novel Compounds with High Affinity, Selectivity and Biological Efficacy at Sigma Receptors” J. Pharmacol. Exp. Ther. 262(1):32-40.
Cardiome Drug Effective for Heart Patients. Press Release, Sep. 3, 2002, 3 pages.
Cardiome Pharma Corp. Healthcare (Underweight) Company Report Dec. 12, 2002. 26 pages.
Cardiome Pharma Completes Phase I Safety Study. New Release Transmitted By CNN Newswire, Jul. 30, 2001. 2 pages.
Cardiome Reports Dosing of First Patient in Pivotal Phase II Study. Press Release Jan. 17, 2002. 3 pages.
Cardiome Reports Oral Absorption of RSD1235 in Humans. News Release via Canada Newswire (2002). 3 pages.
Clohs, L. et al., (2002) “Validation of a capillary electrophoresis assay for assessing the metabolic stability of
Bain Allen I
Beatch Gregory N
Longley Cindy J
Plouvier Bertrand M C
Sheng Tao
Anderson Rebecca
Cardiome Pharma Corp.
Saeed Kamal A.
Seed IP Law Group PLLC
LandOfFree
Ion channel modulating compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ion channel modulating compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ion channel modulating compounds and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3572704